EUVIMEDEUVIMED entdecken
Multizentrische Studie

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

Margherita Rimini, Gianluca Masi, Sara Lonardi, Federico Nichetti, Tiziana Pressiani, Daniele Lavacchi, Lucchetti Jessica, Guido Giordano, Mario Scartozzi, Emiliano Tamburini, Alessandro Pastorino, Ilario Giovanni Rapposelli und 37 weitere

Targeted Oncology · 2024

DOI: 10.1007/s11523-024-01060-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Targeted Oncology, 2024. Verfasst von Margherita Rimini und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Gemcitabine, Cisplatin, Deoxycytidine, Biliary Tract Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The TOPAZ-1 phase III trial reported a survival benefit with the anti-programmed cell death ligand 1 (anti-PD-L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). OBJECTIVE: The present study investigated for the first time the impact on survival of adding durvalumab to cisplatin/gemcitabine compared with cisplatin/gemcitabine in a real-world setting. PATIENTS AND METHODS: The analyzed population included patients with unresectable, locally advanced, or metastatic BTC treated with durvalumab in combination with cisplatin/gemcitabine or with cisplatin/gemcitabine alone. The impact of adding durvalumab to chemotherapy in terms of overall survival (OS) and progression free survival (PFS) was investigated with univariate and multivariate analysis. RESULTS: Overall, 563 patients were included in the analysis: 213 received cisplatin/gemcitabine alone, 350 received cisplatin/gemcitabine plus durvalumab. At the univariate analysis, the addition of durvalumab was found to have an impact on survival, with a median OS of 14.8 months versus 11.2 months [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.50-0.80, p = 0.0002] in patients who received cisplatin/gemcitabine plus durvalumab compared to those who received cisplatin/gemcitabine alone. At the univariate analysis for PFS, the addition of durvalumab to cisplatin/gemcitabine demonstrated a survival impact, with a median PFS of 8.3 months and 6.0 months (HR 0.57, 95% CI 0.47-0.70, p 70 years old and those affected by locally advanced disease experiencing the highest survival benefit. Finally, an exploratory analysis of prognostic factors was performed in the cohort of patients who received durvalumab: neutrophil-lymphocyte ratio (NLR) and disease stage were to be independent prognostic factors in terms of OS. The interaction test highlighted NLR ≤ 3, Eastern Cooperative Oncology Group Performance Status (ECOG PS) = 0, and locally advanced disease as positive predictive factors for OS on cisplatin/gemcitabine plus durvalumab. CONCLUSION: In line with the results of the TOPAZ-1 trial, adding durvalumab to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms of OS and PFS in a real-world setting of patients with advanced BTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineCisplatinDeoxycytidineBiliary Tract NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalHumansMaleFemaleRetrospective StudiesAgedMiddle AgedAdultAged, 80 and over

Substanzen

GemcitabineCisplatinDeoxycytidineAntibodies, Monoclonaldurvalumab

Autor:innen und Institutionen

  • Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • Division of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa University Hospital, Pisa, Italy.
  • Dept of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Via Venezian 1, 20133, Milan, Italy.
  • Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

ORCID-Profile: Andrea Casadei-Gardini

Zitieren

APA

Rimini, M., Masi, G., Lonardi, S., Nichetti, F., Pressiani, T., Lavacchi, D., Jessica, L., Giordano, G., Scartozzi, M., Tamburini, E., Pastorino, A., Rapposelli, I. G., Daniele, B., Martinelli, E., Garajova, I., Aprile, G., Schirripa, M., Formica, V., Salani, F., …, & Casadei-Gardini, A. (2024). Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. Targeted Oncology. https://doi.org/10.1007/s11523-024-01060-1

Vancouver

Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, et al. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. Targeted Oncology. 2024. doi:10.1007/s11523-024-01060-1

BibTeX
@article{Rimini2024,
  author = {Rimini, Margherita and Masi, Gianluca and Lonardi, Sara and Nichetti, Federico and Pressiani, Tiziana and Lavacchi, Daniele and Jessica, Lucchetti and Giordano, Guido and Scartozzi, Mario and Tamburini, Emiliano and Pastorino, Alessandro and Rapposelli, Ilario Giovanni and Daniele, Bruno and Martinelli, Erika and Garajova, Ingrid and Aprile, Giuseppe and Schirripa, Marta and Formica, Vincenzo and Salani, Francesca and Winchler, Costanza and Bergamo, Francesca and Balsano, Rita and Gusmaroli, Eleonora and Lorenzo, Angotti and Landriscina, Matteo and Pretta, Andrea and Toma, Ilaria and Pirrone, Chiara and Diana, Anna and Leone, Francesco and Brunetti, Oronzo and Brandi, Giovanni and Garattini, Silvio Ken and Satolli, Maria Antonietta and Rossari, Federico and Fornaro, Lorenzo and Niger, Monica and Zanuso, Valentina and De Rosa, Antonio and Ratti, Francesca and Aldrighetti, Luca and De Braud, Filippo and Foti, Silvia and Rizzato, Mario Domenico and Vivaldi, Caterina and Stefano, Cascinu and Rimassa, Lorenza and Antonuzzo, Lorenzo and Casadei-Gardini, Andrea},
  title = {Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study},
  journal = {Targeted Oncology},
  year = {2024},
  doi = {10.1007/s11523-024-01060-1}
}
Kostenlos starten →